Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126839051 | 12683905 | 1 | I | 20160715 | 20160812 | 20160825 | 20160825 | EXP | GB-MHRA-EYC 00142693 | GB-TEVA-685551ACC | TEVA | 86.00 | YR | F | Y | 57.00000 | KG | 20160825 | OT | GB | GB |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126839051 | 12683905 | 1 | PS | GABAPENTIN. | GABAPENTIN | 1 | Oral | 900 MILLIGRAM DAILY; | N | U | 76017 | 300 | MG | TID | |||||
126839051 | 12683905 | 2 | SS | LANSOPRAZOLE. | LANSOPRAZOLE | 1 | Oral | 30 MILLIGRAM DAILY; | U | 77255 | 30 | MG | QD | ||||||
126839051 | 12683905 | 3 | C | INSULIN | INSULIN NOS | 1 | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126839051 | 12683905 | 1 | Neuralgia |
126839051 | 12683905 | 3 | Type 2 diabetes mellitus |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
126839051 | 12683905 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126839051 | 12683905 | Acute kidney injury |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |